Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
microRNA 3065 (MIR3065) is a predicted microRNA, classified as a non-coding RNA molecule. MicroRNAs are short, single-stranded RNA species of approximately 21–25 nucleotides, produced via the Drosha-DGCR8-Dicer pathway, and incorporated into the RNA-induced silencing complex (RISC), where they guide recognition and post-transcriptional repression (via mRNA cleavage or translational inhibition) of target mRNAs[2][3]. While many microRNAs are functionally characterized, microRNA 3065 itself is not widely referenced in the scientific literature; there is currently no substantial evidence designating it as a validated, disease-relevant target, nor are there data regarding its interaction with drugs, use as a biomarker, or its role in pathology.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on microRNA 3065 (MIR3065).